化疗与生物疗法联合治疗癌症的基本原理。

Molecular biotherapy Pub Date : 1990-12-01
R O Dillman
{"title":"化疗与生物疗法联合治疗癌症的基本原理。","authors":"R O Dillman","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Chemotherapy and biotherapy are the two systemic modalities available for cancer treatment. In vitro assays and animal studies suggest various rationales for combining these two modalities. The first approach is to take advantage of apparent additive or synergistic cytotoxic and/or cytostatic effects of both modalities. A second approach is the use of chemotherapy to maximally cytoreduce tumor, followed by biotherapy to restore the immune system and/or to enhance immunologic elimination of microscopic tumor. The third approach uses biotherapy to diminish chemotherapy toxicities so that higher and more intense doses of chemotherapy can be used. The fourth approach involves the use of biologics to modify the tumor environment in order to enhance the delivery of chemotherapy molecules. A fifth approach is the use of chemotherapy as a biologic response modifier to enhance antitumor effects of biotherapy. The sixth strategy is to use biologics to reduce or overcome cell resistance to chemotherapy. Clinical trials are in progress exploring these various strategies. The end point of all of these approaches must be an improved risk to benefit or toxicity to efficacy ratio in the context of cancer treatment.</p>","PeriodicalId":18809,"journal":{"name":"Molecular biotherapy","volume":"2 4","pages":"201-7"},"PeriodicalIF":0.0000,"publicationDate":"1990-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Rationales for combining chemotherapy and biotherapy in the treatment of cancer.\",\"authors\":\"R O Dillman\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Chemotherapy and biotherapy are the two systemic modalities available for cancer treatment. In vitro assays and animal studies suggest various rationales for combining these two modalities. The first approach is to take advantage of apparent additive or synergistic cytotoxic and/or cytostatic effects of both modalities. A second approach is the use of chemotherapy to maximally cytoreduce tumor, followed by biotherapy to restore the immune system and/or to enhance immunologic elimination of microscopic tumor. The third approach uses biotherapy to diminish chemotherapy toxicities so that higher and more intense doses of chemotherapy can be used. The fourth approach involves the use of biologics to modify the tumor environment in order to enhance the delivery of chemotherapy molecules. A fifth approach is the use of chemotherapy as a biologic response modifier to enhance antitumor effects of biotherapy. The sixth strategy is to use biologics to reduce or overcome cell resistance to chemotherapy. Clinical trials are in progress exploring these various strategies. The end point of all of these approaches must be an improved risk to benefit or toxicity to efficacy ratio in the context of cancer treatment.</p>\",\"PeriodicalId\":18809,\"journal\":{\"name\":\"Molecular biotherapy\",\"volume\":\"2 4\",\"pages\":\"201-7\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1990-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Molecular biotherapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular biotherapy","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

化疗和生物疗法是两种可用于癌症治疗的全身方式。体外实验和动物实验显示了将这两种方法结合起来的各种理由。第一种方法是利用两种方式明显的加性或协同细胞毒性和/或细胞抑制作用。第二种方法是使用化疗来最大限度地减少肿瘤细胞,然后使用生物疗法来恢复免疫系统和/或增强对微观肿瘤的免疫消除。第三种方法是使用生物疗法来减少化疗的毒性,以便使用更高、更大剂量的化疗。第四种方法涉及使用生物制剂来改变肿瘤环境,以增强化疗分子的递送。第五种方法是使用化疗作为生物反应调节剂来增强生物治疗的抗肿瘤效果。第六种策略是使用生物制剂来减少或克服细胞对化疗的耐药性。临床试验正在探索这些不同的策略。在癌症治疗的背景下,所有这些方法的终点必须是改善风险-获益或毒性-疗效比。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Rationales for combining chemotherapy and biotherapy in the treatment of cancer.

Chemotherapy and biotherapy are the two systemic modalities available for cancer treatment. In vitro assays and animal studies suggest various rationales for combining these two modalities. The first approach is to take advantage of apparent additive or synergistic cytotoxic and/or cytostatic effects of both modalities. A second approach is the use of chemotherapy to maximally cytoreduce tumor, followed by biotherapy to restore the immune system and/or to enhance immunologic elimination of microscopic tumor. The third approach uses biotherapy to diminish chemotherapy toxicities so that higher and more intense doses of chemotherapy can be used. The fourth approach involves the use of biologics to modify the tumor environment in order to enhance the delivery of chemotherapy molecules. A fifth approach is the use of chemotherapy as a biologic response modifier to enhance antitumor effects of biotherapy. The sixth strategy is to use biologics to reduce or overcome cell resistance to chemotherapy. Clinical trials are in progress exploring these various strategies. The end point of all of these approaches must be an improved risk to benefit or toxicity to efficacy ratio in the context of cancer treatment.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Innovation in science. Pretreatment natural killer antigen density correlates to clinical response in tumor patients receiving long-term subcutaneous recombinant interleukin-2 and recombinant interferon-alpha. The role of cytokines in tumor immunotherapy. Report on the 2nd Frankfurt International Cytokine Symposium 25-27 June 1992, Frankfurter Hof, Frankfurt, Germany. Relation between the biologic activities and chemical structures of synthetic microbial lipopeptide analogs in mice. Antitumor effect of recombinant human tumor necrosis factor-alpha analog combined with desmuramyl dipeptides LK-409 or LK-410 on sarcoma in mice.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1